FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if COVID-19 symptoms return
By Zoey BeckerMay 5, 2022 07:30am
Pfizer
https://www.fiercepharma.com/pharma/fda-rebukes-pfizers-sugg…
Pfizer received an emergency use authorization from the FDA in December to sell its antiviral, the first of its kind to fight COVID-19. Since then, the U.S. has ordered 20 million courses and is working to bolster the pill’s availability. The drug is heavily endorsed by the Biden administration and was even prescribed to Kamala Harris. Despite the accolades, it’s not in as high demand as anticipated, and it recently was found ineffective for post-exposure protection.
The pill is prescribed as a five-day course, and its directions read that it is “not authorized for use for longer than 5 consecutive days.”
Paxlovid garnered Pfizer $1.5 billion in sales in the first quarter, and the company forecasts $22 billion in global sales from the product this year.